Search results
Results from the WOW.Com Content Network
In June 2022, Pfizer and Moderna developed bivalent vaccines to protect against the SARS-CoV-2 wild-type and the Omicron variant. The bivalent vaccines are well-tolerated and offer immunity to Omicron superior to previous mRNA vaccines. [271] In September 2022, the United States Food and Drug Administration (FDA) authorized the bivalent vaccines.
A new variant known as FL.1.5.1, a descendant of omicron, has become more dominant in the US in recent weeks and is now accounting for 14.5 per cent of all Covid cases nationwide, data from the ...
The XEC variant has become the second-most prevalent strain in the country, representing more than 1 in 10 cases, according to data from the Centers for Disease Control and Prevention (CDC). (It ...
The CDC and WHO assessed that the "public health risk posed by this variant is low compared with other circulating variants". [23] Moderna and Pfizer have stated that their COVID-19 vaccines targeted at the omicron variant remain effective against BA.2.86 [ 24 ] and Novavax has stated its updated protein-based COVID-19 vaccine appears effective ...
The agency also evaluated data from human studies of bivalent booster vaccines developed by Pfizer and Moderna targeting Omicron BA.1, an earlier version of the virus that is no longer circulating ...
In September 2023, the FDA approved an updated a monovalent (single) component Omicron variant XBB.1.5 version of the vaccine (Spikevax 2023-2024 formula) as a single dose for individuals aged twelve years of age and older; [203] and authorized the Moderna COVID-19 Vaccine 2023-2024 formula under emergency use for individuals aged 6 months ...
The U.S. Food and Drug Administration on Wednesday authorized updated COVID-19 booster shots from Pfizer /BioNTech and Moderna that target the dominant BA.4 and BA.5 Omicron subvariants, as the ...
The Omicron variant features as such for the first time in the overview of WHO's weekly operational update, namely "Supporting Omicron variant detection and COVID-19 response in southern Africa." As of 2 December, Botswana and South Africa have reported 19 and 172 Omicron variant cases, respectively, accounting for 62% of global cases.